Related Experiment Video
Updated: May 18, 2026
09:09
Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
Published on: June 23, 2020
A functionalized poly(amidoamine) nanocarrier-loading 5-fluorouracil: pH-responsive drug release and enhanced
Lina Du1, Yiguang Jin, Jiangyong Yang
1Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, China.
Anti-Cancer Drugs
|September 20, 2012
Summary
A novel poly(amidoamine) (PAMAM) nanocarrier, PAMAM-pDEA-mPEG, was developed for enhanced anticancer drug delivery. This pH-responsive system effectively loaded and released 5-fluorouracil (5-FU), showing improved efficacy in preclinical models.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Drug Delivery Systems
Background:
- Developing effective drug delivery systems is crucial for improving cancer therapy.
- Poly(amidoamine) (PAMAM) nanocarriers offer potential due to their tunable properties.
- pH-responsive materials can enhance targeted drug release in tumor microenvironments.
Purpose of the Study:
- To design and synthesize a functionalized PAMAM nanocarrier (PAMAM-pDEA-mPEG) for targeted anticancer drug delivery.
- To evaluate the pH-responsive drug loading and release characteristics of the nanocarrier.
- To assess the in vitro and in vivo efficacy and safety of the drug-loaded nanocarrier.
Main Methods:
- Synthesis of PAMAM-pDEA-mPEG copolymer using atom transfer radical polymerization and click chemistry.
- Drug loading of 5-fluorouracil (5-FU) into the nanocarrier core.
- In vitro evaluation of pH-dependent drug release profiles.
- Cytotoxicity and in vivo anticancer efficacy studies in tumor-bearing mice.
Main Results:
- The PAMAM-pDEA-mPEG nanocarrier exhibited a core-shell structure with pH-sensitive pDEA and stabilizing mPEG layers.
- High drug loading efficiency of 5-FU was achieved.
- The nanocarrier demonstrated significantly higher drug release at pH 6.5 (tumor environment) compared to pH 7.4 (physiological environment).
- The 5-FU-loaded nanocarrier showed enhanced anticancer effects and good biocompatibility in vivo.
Conclusions:
- The synthesized PAMAM-pDEA-mPEG nanocarrier is a promising platform for pH-responsive delivery of anticancer drugs like 5-FU.
- The nanocarrier's design facilitates targeted drug release in the tumor microenvironment, improving therapeutic efficacy.
- This functionalized nanocarrier represents a significant advancement in cancer drug delivery systems.
Related Concept Videos
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...